Lymphoma in the Orbit

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT01302912
First received: February 23, 2011
Last updated: November 3, 2011
Last verified: November 2011
  Purpose

Imaging techniques have considerably improved over the last decades and ocular adnexal lymphomas (OALs) nowadays can be detected. As major advances in immunophenotyping and molecular diagnostics in histology have been achieved offering an accurate diagnosis, the investigators would like to introduce that surgical biopsy of an orbital lymphoma becomes crucial for the possibility of a correct diagnosis and proper treatment. As radiotherapy accomplished great preciseness as well and OALs respond excellently to radiation, this therapy should be the treatment of choice in local defined lymphomas instead of blind treatment with steroids. Radiation results in great local control rates of 85% to 100%

  • Trial with surgical intervention

Condition Intervention Phase
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
Procedure: Lymphoma-Biopsy
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Estimated Enrollment: 50
Study Start Date: February 2011
Estimated Study Completion Date: May 2012
Intervention Details:
    Procedure: Lymphoma-Biopsy
    Patients after biopsy of orbital lymphoma
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patient, who underwent biopsy of an ocular adnexal lymphoma between 01/2006 and 12/2010 at the University Hospital Zurich, Division of Ophthalmology

Criteria

Inclusion criteria: - both genders

  • >17 years of age
  • underwent biopsy of an ocular adnexal lymphoma between 01/2006 and 12/2010 at the University Hospital Zurich, Division of Ophthalmology
  • diagnosis histologically proven

Exclusion criteria:

  • less than 18 years of age
  • patient underwent no MRI before surgery (biopsy)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01302912

Locations
Switzerland
University Hospital Zurich, Ophthalmic Clinic
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Karla Chaloupka, MD University Hospital Zurich, Ophtalmic Clinic
  More Information

No publications provided

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01302912     History of Changes
Other Study ID Numbers: USZ-OALs-Register
Study First Received: February 23, 2011
Last Updated: November 3, 2011
Health Authority: Switzerland: UZurich

Keywords provided by University of Zurich:
ocular adnexal lymphomas

Additional relevant MeSH terms:
Lymphoma
Lymphoma, B-Cell, Marginal Zone
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin

ClinicalTrials.gov processed this record on April 17, 2014